AstraZeneca PLC (AZN)vsSS Innovations International Inc. Common Stock (SSII)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
SSII
SS Innovations International Inc. Common Stock
$3.31
+0.30%
HEALTHCARE · Cap: $645.24M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 117000% more annual revenue ($61.37B vs $52.41M). AZN leads profitability with a 17.0% profit margin vs -23.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SSII
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+86.9%
Fair Value
$25.38
Current Price
$3.31
$22.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 39.4% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 12.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : SSII
The strongest argument for SSII centers on Revenue Growth, Debt/Equity. Revenue growth of 39.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : SSII
The primary concerns for SSII are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while SSII is a hypergrowth play — different risk/reward profiles.
SSII carries more volatility with a beta of 0.58 — expect wider price swings.
SSII is growing revenue faster at 39.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 22/100), backed by strong 17.0% margins. SSII offers better value entry with a 86.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
SS Innovations International Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
SS Innovations International, Inc., is a commercial-stage surgical robotics company in India and internationally. The company is headquartered in Gurugram, India.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?